NASDAQ · CALC
Healthcare · Biotechnology
$2.02
Down-$0.09 (-4.46%)
Updated Sep 9, 2026, 2:26 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CALC closed at $2.02 after 20 trading sessions, up 207.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 8, 2026 | $2.11 | $2.15 | $1.9915 | $2.02 | 122.61K |
| Sep 4, 2026 | $2.13 | $2.25 | $2.09 | $2.17 | 94.13K |
| Sep 3, 2026 | $2.115 | $2.27 | $2.115 | $2.20 | 94.78K |
| Sep 2, 2026 | $2.02 | $2.215 | $2.02 | $2.10 | 113.72K |
| Sep 1, 2026 | $2.11 | $2.26 | $2.00 | $2.00 | 141.37K |
| Aug 31, 2026 | $2.2998 | $2.4727 | $2.13 | $2.14 | 166.64K |
| Aug 28, 2026 | $2.3305 | $2.382 | $2.20 | $2.322 | 135.21K |
| Aug 27, 2026 | $2.651 | $2.7503 | $2.335 | $2.35 | 299.96K |
| Aug 26, 2026 | $2.9985 | $2.9985 | $2.867 | $2.9375 | 35.47K |
| Aug 25, 2026 | $2.754 | $2.9455 | $2.7345 | $2.94 | 44.15K |
| Aug 24, 2026 | $0.58 | $0.5988 | $0.55 | $0.5564 | 251.19K |
| Aug 21, 2026 | $0.593 | $0.60 | $0.5608 | $0.5728 | 271.59K |
| Aug 20, 2026 | $0.6162 | $0.63 | $0.5695 | $0.5832 | 1.09M |
| Aug 19, 2026 | $0.638 | $0.6587 | $0.57 | $0.6131 | 423.65K |
| Aug 18, 2026 | $0.6657 | $0.6693 | $0.63 | $0.638 | 103.62K |
| Aug 17, 2026 | $0.68 | $0.6926 | $0.6582 | $0.6625 | 75.99K |
| Aug 14, 2026 | $0.6599 | $0.6887 | $0.64 | $0.6751 | 121.22K |
| Aug 13, 2026 | $0.6299 | $0.6899 | $0.6189 | $0.6573 | 458.38K |
| Aug 12, 2026 | $0.66 | $0.67 | $0.6199 | $0.6199 | 210.96K |
| Aug 11, 2026 | $0.6601 | $0.6859 | $0.6374 | $0.6577 | 167.19K |
The latest Smart Investors Daily articles mentioning CALC.
CALC research
Company profile and research snapshot.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Guggenheim | Buy | — |
| Mar 5, 2026 | Oppenheimer | Outperform | — |
| Jan 29, 2026 | HC Wainwright & Co. | Neutral | — |
| May 15, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 27, 2026
CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for
Benzinga · Aug 20, 2026
Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.
Benzinga · Aug 11, 2026
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.28) by 60.71 percent. This is a 12.5 percent decrease over losses of $(0.40) per share from the
Benzinga · Jul 29, 2026
CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibition therapies for serious
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CALC.
